Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.

Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.

Publication date: Mar 23, 2020

To compare the prognostic value of imaging biomarkers derived from a quantitative analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or cutaneous melanoma (Cut-M) treated with immune checkpoint inhibitors (ICIs).

In this retrospective monocentric study, we included 56 patients with non-resectable Muc-M (n?=?24) or Cut-M (n?=?32) who underwent baseline 18F-FDG-PET/CT before treatment with ICIs between 2011 and 2017. Parameters were extracted from (i) tumoral tissues: SUVmax, SUVmean, TMTV (total metabolic tumor volume), and TLG (total lesion glycolysis) and (ii) lymphoid tissues: BLR (bone marrow-to-liver SUVmax ratio) and SLR (spleen-to-liver SUVmax ratio). Association with survival and response was evaluated using Cox prediction models, Student’s t tests, and Spearman’s correlation respectively. p?

Seban, R.D., Moya-Plana, A., Antonios, L., Yeh, R., Marabelle, A., Deutsch, E., Schwartz, L.H., G’omez, R.G.H., Saenger, Y., Robert, C., Ammari, S., and Dercle, L. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. 26212. 2020 Eur J Nucl Med Mol Imaging.

Concepts Keywords
Biomarkers Prognostic imaging biomarkers
Bone Marrow Medicine
Correlation Branches of biology
FDG Clinical medicine
Glycolysis Neuroimaging
Lesion Melanoma
Liver Biomarkers
Lymphoid Medical physics
Melanoma Medicinal radiochemistry
Metastatic Positron emission tomography
PET Imaging biomarker
PET CT PET-CT
SLR Mucosal melanoma
Spleen Tomography
Tumor

Semantics

Type Source Name
drug DRUGBANK Fludeoxyglucose F-18
disease MESH melanoma
pathway KEGG Melanoma
disease MESH tumor
pathway REACTOME Glycolysis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *